Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harvoni for HCV-Associated Indolent B-Cell Non-Hodgkin's Lymphoma
NCT03261349Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ledipasvir in B-cell non-Hodgkin lymphoma, sponsored by National Taiwan University Hospital. Primary endpoint: The complete remission rate at 1 year. Status: unknown.
02
Drugs
ledipasvir
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03261349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261349.